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Abstract
Purpose Genetic factors have been implicated in the pathogenesis of renal cell carcinoma (RCC), with around 3% of cases 
having a family history. A greater knowledge of the genetics of inherited RCC has the potential to translate into novel thera-
peutic targets for sporadic RCC.
Methods A literature review was performed summarising the current knowledge on hereditary RCC diagnosis, surveillance 
and management.
Results Familial RCC is usually inherited in an autosomal dominant manner, although inherited RCC may present without a 
relevant family history. A number of familial RCC syndromes have been identified. Familial non-syndromic RCC is suspected 
when ≥ 2 relatives are affected in the absence of syndromic features, although clear diagnostic criteria are lacking. Young age 
at onset and bilateral/multicentric tumours are recognised characteristics which should prompt molecular genetic analysis. 
Surveillance in individuals at risk of inherited RCC aims to prevent morbidity and mortality via early detection of tumours. 
Though screening and management guidelines for some inherited RCC syndromes (e.g. von Hippel–Lindau disease, Birt–
Hogg–Dube syndrome, hereditary leiomyomatosis) are well defined for rare cause of inherited RCC (e.g. germline BAP1 
mutations), there is limited information regarding the lifetime RCC risks and the most appropriate screening modalities.
Conclusion Increasing knowledge of the natural history and genetic basis has led to characterisation and tailored management 
of hereditary RCC syndromes. International data sharing of inherited RCC gene variant information may enable evidence-
based improvements in the diagnosis, surveillance protocols and management of these rare conditions.
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Introduction
In addition to smoking, obesity and hypertension, genetic 
factors have been implicated in the pathogenesis of renal cell 
carcinoma (RCC) with around 3% of cases having a family 
history [1]. Familial RCC is usually inherited in an auto-
somal dominant manner (though there may be incomplete 
penetrance). However, patients harbouring a mutation in a 
gene predisposing to RCC do not necessarily have a family 
history of RCC (the mutation may have arisen de novo in the 
proband or the mutation may be non-penetrant in a carrier 
parent. If there is no family history, hereditary RCC might 
be suspected by the presence of bilateral/multicentric or 
young onset RCC and then confirmed by molecular genetic 
analysis. In addition, the presence of additional (non-RCC) 
clinical features in the proband or close relatives might sug-
gest a specific multisystem hereditary RCC syndrome [e.g. 
pulmonary cysts in Birt–Hogg–Dube syndrome (see Fig. 1), 
cerebellar haemangioblastomas in von Hippel–Lindau dis-
ease; cutaneous or uterine leiomyomas in HLRCC, etc. (see 
later)]. Histopathological features or immunohistochemical 
investigations may also guide molecular genetic investiga-
tions (Table 1 and Fig. 1).
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Methods
A non-systematic literature search was conducted using 
Medline, updated to December 2017. The reference lists of 
selected manuscripts were checked manually for eligible 
articles. The most relevant articles summarising existing 
knowledge on hereditary RCC syndromes, including diag-
nosis, management and surveillance, were selected for this 
review.
Results
Major inherited forms of RCC 
von Hippel–Lindau disease
This rare autosomal dominantly inherited disorder has an 
incidence of approximately 1 in 30,000 and is caused by 
constitutional mutations in the VHL tumour suppressor 
gene (TSG) [2, 3]. In most cases, the lifetime risks of reti-
nal and central nervous haemangioblastomas and clear 
cell RCC are over 70% each [4, 5]. Less frequent tumours 
include phaeochromocytoma/paraganglioma (approxi-
mately 20% of cases), pancreatic neuroendocrine tumours 
(approximately 10%) and endolymphatic sac tumours 
(approximately 5–10%). Multiple visceral cysts (renal, 
pancreatic and epididymal) are common and may help 
indicate the diagnosis. More than 95% of patients with 
VHL disease will have a detectable VHL gene mutation 
and well-defined genotype–phenotype mean that the nature 
of the mutation may predict likely tumour risks (e.g. risk 
of phaeochromocytoma is small with truncating muta-
tions and exonic deletions) [3, 5]. The VHL gene product 
has a critical role in regulating the hypoxic gene response 
through stability of the α-subunits of the HIF-1 and HIF-2 
transcription factors [6–8]. This knowledge provides the 
rationale for the use of antiangiogenic tyrosine kinase 
inhibitors (e.g. sunitinib/sorafenib) in sporadic RCC, as 
most clear cell RCC have somatic mutations in the VHL 
TSG [3]. Patients with VHL disease and asymptomatic 
family members found to carry the familial mutation are 
Fig. 1  Examples of radiological, histological and immunohisto-
chemical features that might suggest an inherited predisposition 
to renal cell carcinoma. Upper panel: a high-resolution CT thorax 
showing multiple basal cysts in a patient with Birt–Hogg–Dube syn-
drome (reprinted with permission from [52]). Lower panel: b the 
H + E-stained histological appearance of an SDHB-deficient RCC. 
There is evidence of intracytoplasmic vacuoles marked by the black 
arrow. c Loss of SDHB protein expression on immunostaining of the 
RCC tumour in the lower part of the image, with SDHB staining pre-
sent in the adjacent normal renal tissue visible in the upper image. 
(Reprinted with permission from [39])
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screened annually to detect asymptomatic tumours [full 
details of the surveillance programmes are published else-
where (10, 11), but generally renal screening is by annual 
MRI from age 16 years] and enable early intervention 
(small RCC are usually removed when they reach 3 cm 
diameter) [9–11].
Birt–Hogg–Dubé syndrome
Birt–Hogg–Dubé (BHD) syndrome is characterised by an 
autosomal dominantly inherited predisposition to multiple 
fibrofolliculomas (characteristically on the face), lung cysts 
and pneumothorax, renal cell carcinoma and possibly colo-
rectal tumours [12, 13]. The risk of RCC in BHD syndrome 
is significantly less than that in VHL disease (approximately 
25%), but annual renal surveillance (usually by MRI or 
renal ultrasonography if MRI is unavailable or not toler-
ated) is offered to patients and mutation carriers from age 
20 years [13]. Though the characteristic RCC histology 
contains chromophobe and oncocytic elements, other sub-
types, including clear cell RCC, are well described [14, 15]. 
Germline inactivating mutations in the FLCN TSG can cause 
both BHD syndrome and non-syndromic familial pneumo-
thorax. The function of the FLCN gene product has not been 
fully elucidated; however, inactivation leads to activation of 
the mTOR pathway [16, 17].
Hereditary leiomyomatosis and renal cell cancer
The presence of multiple cutaneous leiomyomas in a patient 
with RCC suggests a diagnosis of hereditary leiomyomatosis 
and renal cell cancer (HLRCC). This very rare disorder (inci-
dence approximately 1 in 200,000) is caused by inactivating 
mutations in the FH gene which encodes fumarate hydratase, 
a key component of the tricarboxylic acid (Krebs) cycle [18]. 
Affected females may present with early-onset multiple uter-
ine leiomyomas (fibroids) and FH mutations are a rare cause 
of inherited phaeochromocytoma/paraganglioma [19–21]. 
RCC in HLRCC is typically classified as Type 2 papillary 
RCC or collecting duct RCC [22]. Though the lifetime risk 
of RCC in this condition is around 15%, it is typically an 
aggressive early metastatic tumour that can occur at a young 
Table 1  Overview of major hereditary renal cell cancer syndromes. Adapted from Menko and Maher [1]
AD autosomal dominant, RCC renal cel carcinoma
a Inheritance is characterised by maternal imprinting
Syndrome Inheritance Gene Estimated RCC risk Renal tumour histological 
subtypes
Functional consequences of 
mutation
Von Hippel–Lindau disease AD VHL 70% Clear cell RCC Activation of hypoxic 
response pathways
Birt–Hogg–Dubé syn-
drome
AD FLCN 25% Various, but hybrid chro-
mophobe/oncocytic RCC 
typical
Activation of the mTOR 
pathway
Hereditary type 1 papillary 
RCC 
AD MET Increased Papillary type 1 RCC Activation of MET signal-
ling pathway
Hereditary leiomyomatosis 
and renal cell cancer
AD FH 15% Papillary type 2 RCC Activation of hypoxic 
response pathways
Epigenetic changes (e.g. 
DNA methylation)
Succinate dehydrogenase 
subunit-related RCC 
AD SDHB
SDHDa
SDHC
SDHA
Highest risk (up 
to 10–15% with 
SDHB
Various types, but specific 
features recognised 
Activation of hypoxic 
response pathways
Epigenetic changes (e.g. 
DNA methylation)
Chromosome 3 transloca-
tions
Chromosomal Chromosome 3 Increased (up to 70%) Clear cell RCC Loss of translocated chro-
mosome 3p and somatic 
mutation of VHL leads 
to activation of hypoxic 
response pathways
PTEN hamartoma tumour 
syndrome
AD PTEN 5–35% Mostly papillary RCC Activation of phospho-
inositide 3-kinase (PI3K) 
signalling pathway
Hereditary BAP1 tumour 
syndrome
AD BAP1 Increased Clear cell BAP1 inactivation associ-
ated with altered chro-
matin architecture, DNA 
damage response and cell 
cycle regulation
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age (mean 41 years, earliest report at 11 years) and therefore 
annual surveillance (by MRI as tumours may not be visual-
ised by ultrasonography) is offered [19].
Succinate dehydrogenase‑related RCC 
Succinate dehydrogenase (SDH) is a tetrameric enzyme 
(encoded by the SDHA, SDHB, SDHC and SDHD genes) 
that is upstream of fumarate hydratase in the tricarboxylic 
acid (Krebs) cycle. Germline mutations in these SDHx were 
initially described in association with phaeochromocytoma/
paraganglioma and head and neck paraganglioma (HNPGL), 
but the tumour spectrum has since expanded to include gas-
trointestinal stromal tumours, pituitary tumours and RCC 
[23–27]. A variety of histopathological subtypes have been 
described in SDHx-associated RCC, but recently a distinc-
tive histopathology that should prompt molecular genetic 
investigations has been defined [28]. Though RCC has been 
associated with mutations in each of the subunits, the most 
commonly associated gene is SDHB. Germline mutations 
in SDHB may present with a familial RCC-only phenotype 
[26]. The lifetime risk of RCC in SDHB mutation carriers 
is not well defined, but likely less than 10–15%; however, 
annual or biannual renal surveillance by MRI can be com-
bined with screening for phaeochromocytoma/paragangli-
oma (which commences in older children).
Hereditary papillary RCC 
Activating mutations in the MET proto-oncogene predispose 
to Type 1 hereditary papillary RCC (HPRC) [29]. This is 
an extremely rare disorder that is inherited as an autosomal 
dominant trait with incomplete penetrance. Annual renal 
surveillance by MRI should be offered to patients and at 
risk relatives, but if the patient presents with metastatic RCC 
then treatment with a Met-inhibitor can be considered [30].
Hereditary BAP1‑associated RCC 
Following reports of germline BAP1 mutations in familial 
uveal melanoma, cutaneous melanoma and mesothelioma 
[31, 32], it was recognised that RCCs are also part of the 
BAP1 tumour syndrome spectrum [33, 34]. Though germline 
BAP1 mutations have been described in patients with famil-
ial RCC and no other BAP1-related tumours, such cases are 
rare and BAP1 mutation analysis is not yet performed in all 
cases of inherited RCC. There are no generally agreed sur-
veillance protocols for BAP1 mutation carriers, but, as with 
other inherited cancer predisposition syndromes, repeated 
irradiation should be avoided and therefore surveillance 
should be by MRI rather than CT scanning.
Constitutional chromosome 3 translocations
Constitutional chromosome 3 translocations are a rare, 
but well-validated cause of familial RCC. In patients with 
familial RCC, the detection of a constitutional chromosome 
3 translocation is likely to be relevant (though the trans-
location breakpoints are variable), but if a chromosome 3 
translocation is detected for another reason (e.g. prenatal 
diagnosis) and there is no personal or family history of RCC 
then the risk of RCC is very small [35].
Other rare conditions
A variety of other rare causes of RCC predisposition have 
been described. There has been increasing recognition of 
a significant risk of RCC in patients with Cowden/PTEN 
hamartoma tumour syndrome, but germline PTEN mutations 
are very rare in patients with non-syndromic inherited RCC 
[36]. Tuberose sclerosis may be associated with early-onset 
RCC, but RCC is rare in this condition and renal lesions 
are most commonly angiomyolipomas [37]. Germline VHL, 
SDHx and FH mutations may predispose to phaeochromocy-
toma/paraganglioma and RCC, and on rare occasions renal 
tumours have been reported in association with mutations 
in the phaeochromocytoma genes TMEM127 and MAX [38, 
39]. Germline mutations in CDC73 are associated with 
hyperparathyroidism-jaw tumour syndrome, a very rare 
disorder that has been associated with Wilms tumour and, 
on one occasion, papillary RCC [40].
Familial non‑syndromic RCC 
There are no clear diagnostic criteria for this disorder, 
but broadly this condition is suspected when two or more 
relatives have RCC and there are no features to suggest an 
underlying “syndromic cause” (Table 1). The presence of 
early-onset tumours and/or multiple/bilateral tumours should 
further increase suspicion. Despite the absence of syndro-
mic features, germline mutations in SDHB and FLCN are 
not uncommon in such cases and molecular genetic testing 
for an RCC gene panel [e.g. FLCN, FH, MET, SDHB, VHL 
(± BAP1)] and cytogenetic analysis is generally performed 
in suspected cases. However, in most cases a genetic cause 
is not identified. Some familial cases may result from chance 
or shared environmental factors or polygenic inheritance 
(genome-wide association studies have identified RCC sus-
ceptibility loci), but it is highly suspected that additional 
RCC predisposition genes remain to be identified [41, 42]. 
Familial non-syndromic RCC without an identifiable genetic 
cause is likely to be genetically heterogeneous and clini-
cal studies suggest that autosomal dominant inheritance (in 
inherited cases) is the most likely form of transmission 
[15]. Germline SDHB and FLCN mutations have also been 
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described in non-syndromic early-onset or bilateral RCC 
cases with no family history [15, 25].
Diagnosis of familial RCC 
Young age at onset and bilateral/multicentric tumours are 
well recognised features of inherited syndromic RCC and 
often present in non-syndromic RCC, and these are there-
fore indications for genetic analysis [45]. However, testing of 
individuals at low prior risk for a mutation can lead to diag-
nostic uncertainties from the identification of rare variants 
of uncertain significance (VUSs). In cases of inherited RCC 
with syndromic features, molecular genetic testing can usu-
ally be expected to unequivocally confirm the diagnosis, par-
ticularly for well-characterised genes such as VHL in which 
a wide range of germline mutations have been described 
and VUSs are relatively infrequent. For less well studied 
genes such as BAP1 variant, interpretation can be more 
challenging. Therefore, as suggested for diagnostic testing 
of hereditary phaeochromocytoma and paraganglioma, the 
establishment of agreed gene panels and curated databases 
of inherited RCC-associated gene variants would facilitate 
expert genetic testing [46]. Another issue to be addressed is 
which groups of patients should be offered testing. The mean 
age at diagnosis of symptomatic RCC in VHL disease was 
around 45 years compared to an average age of > 60 years in 
sporadic cases [43], but there is not an agreed age threshold 
at which earlier-onset cases should be tested for RCC predis-
position mutations. Schuh et al. [44] suggested that patients 
with sporadic RCC aged 46 years or younger should trigger 
consideration for germline mutation testing. However, the 
germline mutation detection rate will be low and for those 
that test negative the residual risk of an underlying genetic 
cause is unclear and so other centres have a lower threshold 
for testing (e.g. age 40 years). The low mutation detection 
rate in familial non-syndromic RCC suggests that there are 
further inherited RCC genes to be identified and achieving 
a comprehensive picture of the molecular architecture of 
inherited RCC is necessary for the development of optimal 
evidence-based guidelines for the molecular investigation of 
potential inherited RCC.
Management and surveillance of inherited RCC 
Over the past 25 years, the identification and surveillance of 
large numbers of VHL mutation carriers has led to a broad 
consensus to how they should be investigated and managed. 
In particular, a consensus has developed that small (< 3 cm) 
screen-detected tumours should be managed by active sur-
veillance and then nephron-sparing surgery performed when 
a solid lesion reaches 3 cm in diameter [47]. As an alterna-
tive to partial nephrectomy percutaneous radiofrequency 
ablation has been used to treat small renal lesions in VHL 
disease [51]. In general, the approach to the management of 
RCCs identified through surveillance in VHL disease has 
been extrapolated to individuals with Birt–Hogg–Dube syn-
drome with tumours followed by active surveillance until 
they reach a diameter of 3 cm and then nephron-sparing 
surgery is performed (alternatively, radiofrequency ablation 
may be used to treat smaller tumours) [13]. However, it is 
clear that the “3 cm rule” is not suitable for renal lesions in 
HLRCC, which can metastasise early and are not reliably 
detected by renal ultrasound. Consequently, individuals with 
germline FH mutations undergo annual MRI surveillance 
even though most will not develop a renal lesion and surgical 
intervention is indicated for small screen-detected lesions 
[19]. For individuals with a germline BAP1 mutation, there 
is very limited information on the lifetime risks of RCC and 
the most appropriate screening modalities. International 
data sharing of inherited RCC gene variant information and 
multicentre collaboration to pool results of natural history 
and screening protocols for mutation carriers are required 
to enable evidence-based surveillance programmes to 
be designed. For example, SDHx-associated RCC can be 
aggressive implying that surveillance for early detection is 
important. However, the tumour risks in SDHB mutation 
carriers are significantly less than originally thought and so 
there is (as in FH mutation carriers) a tension between over-
investigation and early detection. This might be addressed 
by the development of biomarkers to identify the subset of 
individuals who will develop RCC and should be targeted 
for screening and/or novel early detection strategies (such as 
circulating tumour DNA biomarkers).
In some patients, particularly those with no previous fam-
ily history, the diagnosis of inherited RCC disorder is only 
made after presentation with metastatic disease. Addition-
ally, in VHL disease patients may develop multiple central 
nervous system haemangioblastomas that are not amena-
ble to surgical treatment because of their critical location. 
Hence, there is a need to develop effective medical thera-
pies for such cases. Most of the known inherited RCC genes 
encode tumour suppressor genes and biallelic inactivation 
of the relevant inherited RCC gene is present in all tumour 
cells. Therefore, in addition to standard therapies for meta-
static RCC, targeted therapies with agents that exploit the 
specific molecular pathways provides a rational approach to 
therapy [48, 49]. The concept of synthetic lethality-based 
interventions is particularly interesting for inherited RCC 
(and haemangioblastomas) in disorders such as VHL dis-
ease, because the kidneys of VHL patients can harbour hun-
dreds of small “tumourlets” with biallelic VHL inactivation, 
some of which will give rise to RCC years later [50]. Hence, 
it could be hypothesised that ablation of such tumourlets by 
administration of a synthetically lethal compound to young 
adults with VHL disease might reduce the risk of RCC at a 
later age. The development of novel therapeutic approaches 
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to inherited RCC will require a deeper knowledge of the nor-
mal function of inherited RCC gene products and the con-
sequences of mutations in the relevant pathways. However, 
a likely outcome of such research would be the potential for 
translating the knowledge of the pathogenesis of inherited 
RCC into novel treatments for sporadic RCC (as exemplified 
in VHL disease and the involvement of VHL inactivation in 
sporadic clear cell RCC).
Conclusion
A number of familial RCC syndromes and inherited non-
syndromic RCC have been identified. The presence of 
bilateral/multicentric or young-onset RCC, syndromic and 
histopathological features should prompt and guide molecu-
lar genetic analysis. The principal strategy for preventing 
morbidity and mortality in individuals at risk of inherited 
RCC is detection of early stage tumours which can then be 
removed (e.g. HLRCC) or followed up to a safe size (e.g. 
3 cm diameter in VHL disease and BHD syndrome) when 
they are removed or ablated. International data sharing of 
inherited RCC gene variant information may enable evi-
dence-based improvements in the diagnosis and manage-
ment of these rare conditions.
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